Biologics process development is undergoing one of the most dynamic periods in its history. Advances in cell culture intensification, purification technology, digital tools, and regulatory science are reshaping how biopharmaceutical companies design, scale, and operate manufacturing processes. What was once driven mainly by incremental yield improvements is now guided by broader objectives: faster development timelines, greater manufacturing flexibility, stronger quality control, and improved lifecycle management.
From continuous manufacturing concepts to modular facilities and AI-supported process monitoring, development teams are being asked to deliver more sophisticated solutions under increasing time and cost pressure. This article explores the most important developments that are redefining biologics process development and explains why they matter for the future of biomanufacturing.
From Batch to Flow: Continuous Manufacturing Becomes Practical
For many years, continuous manufacturing was viewed as an ambitious concept suited mainly to pilot studies or specialist production lines. Today, it is becoming a practical option within mainstream biologics development programmes. Hybrid approaches that combine batch and continuous unit operations are now being adopted to improve equipment utilisation, reduce facility footprints, and achieve more stable process performance.
The appeal lies in consistency and efficiency. Continuous operations allow tighter control of critical process parameters and can reduce the variability that naturally arises in large batch systems. Process development teams are therefore investing more effort in defining dynamic control strategies that manage start-up, steady-state operation, and shutdown conditions. This represents a shift in development philosophy, where understanding process behaviour over time is as important as defining individual operating setpoints.
Automation and real-time monitoring play a central role in this transition. As continuous systems rely heavily on digital control, process development now routinely integrates hardware, software, and analytics from the earliest design stages.
Upstream Intensification: Higher Productivity in Less Time
Upstream development is experiencing a sustained push towards intensification. Strategies such as N-1 perfusion, high inoculation density, and accelerated seed trains are enabling faster ramp-up to productive cultures and higher volumetric output. These approaches shorten development timelines and reduce the overall manufacturing footprint.
Yet higher productivity brings new challenges. As cell densities increase and productivity rises, the margin for error narrows. Small deviations in culture conditions can have a greater impact on product quality attributes such as glycosylation, aggregation, and charge variants. For this reason, upstream development is increasingly focused on metabolic control, feed strategy optimisation, and environmental stability within the bioreactor.
Rather than chasing maximum titre alone, development teams are prioritising balanced performance, where productivity, robustness, and quality consistency are optimised together. This integrated mindset is becoming a defining feature of modern upstream process design.
Downstream Innovation: Keeping Pace with Upstream Gains
As upstream processes generate higher product loads, downstream purification must evolve to handle the increased demand. Traditional purification platforms remain widely used, yet they are being upgraded through improved materials and smarter process design.
High-capacity chromatography resins are helping reduce cycle times and increase throughput, enabling the processing of larger volumes without expanding facility size. At the same time, membrane chromatography is increasingly adopted for polishing and flow-through applications. These technologies support rapid processing, simplify equipment requirements, and align well with single-use manufacturing strategies.
Continuous and multi-column chromatography systems are also gaining attention. By operating at steady state and using resin capacity more efficiently, these systems can improve productivity while supporting consistent product quality. From a development perspective, they require a deeper understanding of breakthrough behaviour, process control, and automation performance. This pushes downstream development into a more data-rich and model-driven environment.
Harvest and clarification steps are also receiving renewed focus. Higher cell densities can increase filtration challenges and the risk of fouling, making robust clarification strategies essential. Process development teams are responding with more structured filter screening, improved harvest conditioning approaches, and closer alignment between upstream culture conditions and downstream process performance.
Single-Use Manufacturing Enters a New Compliance Era
Single-use technologies have transformed biologics manufacturing by enabling flexible facility design and faster deployment. However, their regulatory and quality expectations are becoming more formalised. Extractables and leachables risk management is now a central topic in process development planning.
Rather than treating material compatibility studies as a late-stage activity, development teams are incorporating polymer risk assessment and supplier data review early in the process. This shift reduces the likelihood of unexpected compliance challenges during validation and commercial readiness.
The practical outcome is closer collaboration between process development, quality assurance, and procurement functions. Material selection is no longer driven solely by performance and availability, but also by long-term compliance strategy and lifecycle risk management.
Digital Tools and AI: Smarter Development Through Data
Digitalisation is reshaping how biologics processes are developed, monitored, and optimised. Advanced data platforms, process models, and automated control systems are becoming standard components of modern development workflows.
Process modelling is increasingly used to support the definition of the design space, scale-up decisions, and the development of control strategies. These models help teams explore process behaviour under different conditions without relying entirely on physical experiments. When used effectively, they improve development efficiency and strengthen scientific justification in regulatory submissions.
AI and machine learning tools are also being adopted for tasks such as anomaly detection, trend analysis, and predictive maintenance. However, regulatory expectations around transparency and credibility are rising. When AI outputs influence quality-related decisions, organisations must demonstrate that the tools are reliable, validated, and suitable for their intended purpose.
This is driving a more disciplined approach to digital adoption, where governance, documentation, and lifecycle management of models are treated with the same seriousness as physical equipment qualification.
Modular and Distributed Manufacturing: A New Operating Model
The concept of modular and decentralised manufacturing is gaining traction, particularly for advanced therapies and personalised medicines. Smaller, standardised production units can be deployed closer to patients, reducing logistics complexity and enabling rapid scale-out.
For process development teams, this trend introduces new priorities. Processes must be designed for reproducibility across multiple locations, with strong standard operating procedures and harmonised control strategies. Transferability becomes a central design goal rather than an afterthought.
Analytical methods also take on greater importance. When manufacturing is distributed, consistent measurement and monitoring of critical quality attributes are essential to maintain product comparability and regulatory confidence.
Biosimilars and the Rise of Targeted Development Strategies
Regulatory signals in Europe and other regions point towards more tailored development pathways for biosimilars. Advances in analytical characterisation and manufacturing control are allowing developers to demonstrate similarity with greater precision.
This reinforces the importance of high-quality process development. A robust and consistent manufacturing process strengthens the analytical comparability package and reduces uncertainty during regulatory review. For biosimilar developers, investment in process understanding is directly linked to development efficiency and long-term commercial success.
Rather than following rigid development templates, teams are being encouraged to apply risk-based thinking and scientific justification, aligning development effort with product complexity and residual uncertainty.
The Future of Process Development: Integration Over Isolation
The most striking feature of modern biologics process development is the level of integration now required. Upstream, downstream, analytics, automation, and regulatory strategy are no longer separate silos. Decisions made in early development influence facility design, digital infrastructure, and lifecycle management plans.
Success increasingly depends on designing processes as complete systems that consider productivity, quality, compliance, and flexibility together. Organisations that adopt this integrated approach are better positioned to respond to market demand, regulatory expectations, and technological change.
As biologics pipelines continue to expand and diversify, process development will remain a strategic function at the heart of biopharmaceutical innovation. The tools and approaches available today offer unprecedented capability. The challenge lies in applying them with clarity, discipline, and scientific rigour to build manufacturing processes that are ready for both present needs and future opportunities.
Disclaimer
This article is provided by Open MedScience for general informational and educational purposes only. It does not constitute professional advice, regulatory guidance, or technical recommendations for specific manufacturing processes, facilities, or products. While every effort has been made to ensure accuracy at the time of publication, the biomanufacturing field evolves rapidly, and standards, technologies, and regulatory expectations may change after publication.
Readers should not rely solely on the information contained in this article when making scientific, operational, regulatory, or commercial decisions. Independent verification, consultation with qualified professionals, and reference to official regulatory sources are strongly advised before implementing any strategies or technologies discussed.
Open MedScience accepts no responsibility for any loss, damage, or adverse outcomes arising from the use or interpretation of the information presented. References to specific technologies, methods, or industry practices do not imply endorsement or guarantee of performance or compliance.
The views expressed in this article reflect the author’s perspective at the time of writing and do not necessarily represent the official position of any organisation, regulatory authority, or commercial entity.
home » diagnostic medical imaging blog » Research Methods and Reproducibility »
